Skip to main content
. 2021 Sep 5;22(7-9):465–477. doi: 10.1080/15384047.2021.1949228

Figure 2.

Figure 2.

Overexpression of KLF2 sensitizes breast cancer cells to cisplatin. A, Immunohistochemistry of KLF2 protein in cancer tissues and adjacent normal tissues collected from 53 breast cancer patients. B, The expression of KLF2 in MDA-MB-231 and MCF10A cells determined by RT-qPCR. C, The protein expression of KLF2 in MDA-MB-231 and MCF10A cells determined by Western blot. D, RT-qPCR detection of KLF2 mRNA expression in MDA-MB-231 cells treated with cisplatin or in combination with oe-KLF2. E, The protein expression of KLF2 detected by Western blot in MDA-MB-231 cells treated with cisplatin or in combination with oe-KLF2. F, Viability of MDA-MB-231 cells treated with cisplatin or in combination with oe-KLF2. G, Apoptosis rate of MDA-MB-231 cells treated with cisplatin or in combination with oe-KLF2 detected by flow cytometry. H, Migration and invasion of MDA-MB-231 cells treated with cisplatin or in combination with oe-KLF2 detected by Transwell assay. I, The protein expression of MMP-2, MMP-9, Bax, and Bcl-2 detected by Western blot in MDA-MB-231 cells treated with cisplatin or in combination with oe-KLF2. * p < .05 indicates the comparison between two groups. All experiments were conducted independently in triplicate